Replies to post #161275 on Biotech Values

[genisi]

GRFS/inhaled AAT

Note that Grifols is pursuing the CF indication while Kamada went for the AATD indication as it's first target. Data from Kamada's phase II/III of inhaled AAT is expected by year-end/early 2014.

http://clinicaltrials.gov/show/NCT01217671